MEDIWOUND LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.04 USD | +0.71% |
|
+4.48% | +67.55% |
| May. 29 | Transcript : MediWound Ltd., Q1 2024 Earnings Call, May 29, 2024 | |
| May. 29 | Earnings Flash (MDWD) MEDIWOUND Reports Q1 Revenue $5M, vs. Street Est of $4.7M | MT |
Financials (USD)
| Sales 2024 * | 23.84M | Sales 2025 * | 30.28M | Capitalization | 158M |
|---|---|---|---|---|---|
| Net income 2024 * | -23M | Net income 2025 * | -18M | EV / Sales 2024 * | 6.64 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 5.22 x |
| P/E ratio 2024 * |
-6.59
x | P/E ratio 2025 * |
-8.83
x | Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 73.7% |
More Fundamentals
* Assessed data
More news
Latest transcript on MediWound Ltd.
More recommendations
More press releases
| 1 day | +0.71% | ||
| 1 week | +4.48% | ||
| Current month | +4.48% | ||
| 1 month | -4.00% | ||
| 3 months | -0.41% | ||
| 6 months | +74.59% | ||
| Current year | +67.55% |
1 week
15.86
17.55
1 month
15.3818.18
Current year
10.2019.86
1 year
7.1019.86
3 years
7.1043.54
5 years
7.1043.54
10 years
7.1089.25
| Managers | Title | Age | Since |
|---|---|---|---|
Ofer Gonen
CEO | Chief Executive Officer | 50 | 03-08-31 |
Hani Luxenburg
DFI | Director of Finance/CFO | 52 | 23-05-13 |
Robert Snyder
CTO | Chief Tech/Sci/R&D Officer | 75 | 22-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Stephen Wills
BRD | Director/Board Member | 67 | 17-03-31 |
David Fox
BRD | Director/Board Member | 66 | 20-04-26 |
Homi Shamir
CHM | Chairman | 70 | 22-07-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-07 | 17.04 | +0.71% | 25,863 |
| 24-06-06 | 16.92 | -0.47% | 53,665 |
| 24-06-05 | 17 | +0.12% | 47,995 |
| 24-06-04 | 16.98 | +2.91% | 45,076 |
| 24-06-03 | 16.5 | +1.16% | 34,078 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotes
Mediwound Ltd is an Israel-based biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Company's portfolio is focused on next-generation protein-based therapies for burn and wound care and tissue repair and includes products such as, NexoBrid, a concentrate of proteolytic enzymes enriched in bromelain, which is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues.; EscharEx biological drug candidate for the debridement of chronic and other hard-to-heal wounds; MW005 a topically applied biological drug candidate for the treatment of non-melanoma skin cancers, based on the same API of NexoBrid and EscharEx products, a concentrate of proteolytic enzymes enriched in bromelain.
Sector
Pharmaceuticals
Calendar
2024-08-05
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
17.04
USD
Average target price
28.5
USD
Spread / Average Target
+67.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +67.55% | 158M | |
| +0.82% | 91.94B | |
| -1.32% | 38.74B | |
| -12.88% | 32.82B | |
| +64.77% | 26.66B | |
| -16.31% | 15.32B | |
| -5.78% | 13.3B | |
| -11.38% | 11.65B | |
| +173.10% | 10.37B | |
| -49.84% | 10.12B |
- Stock Market
- Equities
- MDWD Stock
